In vivo investigation of immune dynamics following cutaneous challenge (VIVID)

GO TO STUDY

Safety and Efficacy of Aneurysms Treated with Endovascular Devices (SEATED)

GO TO STUDY

Cardiovascular

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants with Prior Myocardial Infarction who have Elevated Coronary Inflammation Based on Fat Attenuation Index (FAI) Score Assessed by Coronary Computed Tomography Angiography (CCTA) (FORTIFY)

GO TO STUDY

Predicting Long-Term Success and Identifying Optimal Treatment Strategies for Idiopathic Toe Walking

GO TO STUDY

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) (MTX-463-I201)

GO TO STUDY

Clinical Management and Short-Term Outcomes of Neonates Born at 22 Weeks in UK Neonatal Intensive Care Units

GO TO STUDY

Observational multi-centre study comparing fasciculation frequency detected using motor unit MRI (MUMRI) across scanner make and magnet strength.

GO TO STUDY

A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled Study (Part 1) and Open-Label Extension (Part 2) to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich’s Ataxia Aged 2 to < 16 Years. (BRAVE (296FA301))

GO TO STUDY

Cancer and neoplasms

NX-5948-201 - A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

GO TO STUDY

Neurological

Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome (ION582-CS2 (REVEAL))

GO TO STUDY